In case of emergency, or questions concerning treatments possibly interacting with HEMGENIX® treatment, use following contact information:

Haemophilia treating physician's name:
Phone number/Email:
Hospital/Centre:
Gene therapy physician's name (if different):
Phone number/Email:
Hospital/Centre:
Contact in case of emergency (patient's partner/sibling/other):

Version 1.0 - GBR-HGX-0021 Date of preparation: October 2023

Patient Card

HEMGENIX®▼ (etranacogene dezaparvovec)

Patient's name: _____

Date of HEMGENIX® administration: _____

Carry this card with you at all times after administration of HEMGENIX® and show it to any person who may give you medical care, such as doctors and/or nurses.

Information for patients

- Make sure you attend all regular blood tests and examinations as directed by your doctor.
- Seek immediate medical advice for any symptoms suggestive of a blood clot, sudden chest pain, shortness of breath, sudden onset of muscle weakness, loss of sensation and/or balance, decreased alertness, difficulty in speaking, pain/tenderness in the leg, increased warmth and red or discoloured skin on the leg, swelling of one or both legs.
- **Do not donate blood; semen; or organs, tissues and cells for transplantation.**

▼ This medicine is subject to additional monitoring.
This will allow quick identification of new safety information.
You can help by reporting any side effects you may experience.

Information for healthcare professionals

This patient has been treated with HEMGENIX®, a liver-directed gene therapy medicinal product that expresses the human coagulation factor IX for the treatment of haemophilia B.

If raised alanine aminotransferase (ALT) occurs after HEMGENIX® treatment the patient may need to undergo treatment with corticosteroids to minimise the risk of hepatotoxicity with HEMGENIX®.

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in the patient information leaflet or patient/caregiver guide. You can also report side effects directly to the MHRA via the Yellow Card Scheme. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, call 0800 731 6789 for free, Monday to Friday between 9am and 5pm. By reporting side effects, you can help provide more information on the safety of this medicine. Adverse events should also be reported to CSL Behring UK Ltd on 01444 447 405.